Capsid Experts Hope to Slash the Cost of Gene Therapies

Manufacturing costs for therapies based on adeno-associated viruses (AAV) could fall thanks to careful work on plasmid redesign and cell-line selection by a company with long-term expertise in capsid discovery.

The post Capsid Experts Hope to Slash the Cost of Gene Therapies appeared first on GEN - Genetic Engineering and Biotechnology News.